These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11657803)

  • 1. Commercial sponsorship in the RCPCH.
    Bull Med Ethics; 1999 Jul; No. 149():5-6. PubMed ID: 11657803
    [No Abstract]   [Full Text] [Related]  

  • 2. Guidelines for relationships between industry and the American College of Obstetricians and Gynecologists and its fellows. ACOG Committee Opinion No. 45.
    American College of Obstetricians and Gynecologists [ACOG]. Committee on Ethics
    ACOG Comm Opin; 1985 Oct; No. 45():1 p. PubMed ID: 11660326
    [No Abstract]   [Full Text] [Related]  

  • 3. The relationship between physicians and the pharmaceutical industry: a report of the Royal College of Physicians.
    Royal College of Physicians
    J R Coll Physicians Lond; 1986 Oct; 20(4):3-10. PubMed ID: 11643936
    [No Abstract]   [Full Text] [Related]  

  • 4. AMA's gift guidelines.
    Conley RB
    Food Drug Cosmet Med Device Law Dig; 1993; 10():19-27. PubMed ID: 11654936
    [No Abstract]   [Full Text] [Related]  

  • 5. General Council to consider amendments to CMA policy on MDs' relationships with drug industry.
    Williams JR
    CMAJ; 1993 Aug; 149(3):335-7. PubMed ID: 11659649
    [No Abstract]   [Full Text] [Related]  

  • 6. CMA guidelines on MD-drug industry relations part of international trend.
    Williams JR
    CMAJ; 1992 Feb; 146(3):386-8. PubMed ID: 11654902
    [No Abstract]   [Full Text] [Related]  

  • 7. The CMA's MD-drug industry guidelines offer advice, nothing more.
    Woollard R
    CMAJ; 1991 Dec; 145(11):1498-9. PubMed ID: 11649304
    [No Abstract]   [Full Text] [Related]  

  • 8. CMA guidelines concerning relationship of MDs and drug industry to be revised, board told.
    Sullivan P
    CMAJ; 1993 Jan; 148(2):273-5. PubMed ID: 11652162
    [No Abstract]   [Full Text] [Related]  

  • 9. Infant formula, science, and politics.
    Adelman C
    Policy Rev; 1983; No. 23():107-26. PubMed ID: 11650625
    [No Abstract]   [Full Text] [Related]  

  • 10. Two cheers for the CMA's new guidelines on drug company-MD relations The CMA's MD-drug industry guidelines offer advice, nothing more.
    Rapp MS; Woollard R
    CMAJ; 1991 Dec; 145(11):1497-9. PubMed ID: 11649303
    [No Abstract]   [Full Text] [Related]  

  • 11. University physician-researcher conflicts of interest: the inadequacy of current controls and proposed reform.
    Maatz CT
    High Technol Law J; 1992; 7():137-88. PubMed ID: 11659962
    [No Abstract]   [Full Text] [Related]  

  • 12. Accepting commercial sponsorship. Disclosure helps--but is not a panacea.
    Bero LA
    BMJ; 1999 Sep; 319(7211):653-4. PubMed ID: 10480803
    [No Abstract]   [Full Text] [Related]  

  • 13. Paediatricians question Nestlé's donation.
    Court C
    BMJ; 1994 Jun; 308(6945):1661-2. PubMed ID: 11644548
    [No Abstract]   [Full Text] [Related]  

  • 14. Fraud and misconduct in clinical research.
    Wells F
    Account Res; 1997; 5(1-3):25-38. PubMed ID: 11654814
    [No Abstract]   [Full Text] [Related]  

  • 15. Physicians and the pharmaceutical industry.
    Canadian Medical Association
    CMAJ; 1992 Feb; 146(3):388A-C. PubMed ID: 11654903
    [No Abstract]   [Full Text] [Related]  

  • 16. Guidelines on gifts to physicians from industry: an update.
    American Medical Association. Council on Ethical and Judicial Affairs
    Food Drug Law J; 1992; 47(4):445-58. PubMed ID: 11654909
    [No Abstract]   [Full Text] [Related]  

  • 17. Conclusion: The Equity Project.
    Goldhagen J; Waterston T
    Pediatrics; 2003 Sep; 112(3 Part 2):771-2. PubMed ID: 12949350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fraud and misconduct in clinical research: is it prejudicial to patient safety?
    Wells F
    Adverse Drug React Acute Poisoning Rev; 1992; 11(4):241-55. PubMed ID: 11652183
    [No Abstract]   [Full Text] [Related]  

  • 19. Voluntary self-regulatory codes: what should we expect?
    Lexchin J
    Am J Bioeth; 2003; 3(3):49-50. PubMed ID: 14594491
    [No Abstract]   [Full Text] [Related]  

  • 20. Dealing with research misconduct in the United Kingdom. Deception: difficulties and initiatives.
    Chantler C; Chantler S
    BMJ; 1998 Jun; 316(7146):1731-2. PubMed ID: 9652923
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.